(Q37754763)

22 August 2017

title

Respiratory syncytial virus: immunopathology and control (English)

1 reference

22 August 2017

Weidong Zhang

1

1 reference

22 August 2017

Richard F Lockey

series ordinal

2

1 reference

22 August 2017

Shyam S Mohapatra

series ordinal

3

1 reference

22 August 2017

publication date

1 January 2006

1 reference

Expert Review of Clinical Immunology

22 August 2017

published in

1 reference

22 August 2017

volume

2

1 reference

22 August 2017

issue

1

1 reference

22 August 2017

page(s)

169-179

1 reference

Economic impact of viral respiratory disease in children

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Respiratory syncytial virus infection in elderly and high-risk adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Respiratory syncytial virus and influenza A infections in the hospitalized elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Prevention and treatment of respiratory syncytial virus and parainfluenza viruses in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Differential cytokine mRNA expression in Dermatophagoides farinae allergen-sensitized and respiratory syncytial virus-infected mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Heparin-dependent attachment of respiratory syncytial virus (RSV) to host cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Blocking intercellular adhesion molecule-1 on human epithelial cells decreases respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Synergistic effects of gene-end signal mutations and the M2-1 protein on transcription termination by respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Respiratory syncytial virus nonstructural proteins NS1 and NS2 mediate inhibition of Stat2 expression and alpha/beta interferon responsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Respiratory syncytial virus: the virus, the disease and the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Severity of respiratory syncytial virus infection is related to virus strain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Innate immune recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

A toll-like receptor that prevents infection by uropathogenic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Toll-like receptor 4 is not involved in host defense against respiratory tract infection with Sendai virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Association between common Toll-like receptor 4 mutations and severe respiratory syncytial virus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Respiratory syncytial virus up-regulates TLR4 and sensitizes airway epithelial cells to endotoxin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Increased Toll-like receptor 4 expression in infants with respiratory syncytial virus bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Inhibition of toll-like receptor 7- and 9-mediated alpha/beta interferon production in human plasmacytoid dendritic cells by respiratory syncytial virus and measles virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Differential role for TLR3 in respiratory syncytial virus-induced chemokine expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Expression of respiratory syncytial virus-induced chemokine gene networks in lower airway epithelial cells revealed by cDNA microarrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Macrophage inflammatory protein-1alpha (not T helper type 2 cytokines) is associated with severe forms of respiratory syncytial virus bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Differential production of inflammatory cytokines in primary infection with human metapneumovirus and with other common respiratory viruses of infancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Respiratory syncytial virus-induced chemokine production: linking viral replication to chemokine production in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

RANTES (CCL5) production during primary respiratory syncytial virus infection exacerbates airway disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Role of CCL11 in eosinophilic lung disease during respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Effects of nonstructural proteins NS1 and NS2 of human respiratory syncytial virus on interferon regulatory factor 3, NF-kappaB, and proinflammatory cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Respiratory syncytial virus induces prostaglandin E2, IL-10 and IL-11 generation in antigen presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Respiratory syncytial virus decreases the capacity of myeloid dendritic cells to induce interferon-gamma in naïve T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Immunopathology in RSV infection is mediated by a discrete oligoclonal subset of antigen-specific CD4(+) T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)- but not Th1-driven immunopathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Immunological determinants of disease caused by respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Immune responses and disease enhancement during respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Respiratory syncytial virus infection suppresses lung CD8+ T-cell effector activity and peripheral CD8+ T-cell memory in the respiratory tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Respiratory syncytial virus fusion protein mediates inhibition of mitogen-induced T-cell proliferation by contact

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Natural reinfection with respiratory syncytial virus does not boost virus-specific T-cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Immunopathogenesis of vaccine-enhanced RSV disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Antibody‐Dependent Enhancement, a Possible Mechanism in Augmented Pulmonary Disease of Respiratory Syncytial Virus in the Bonnet Monkey Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

The Development of Respiratory Syncytial Virus-Specific IgE and the Release of Histamine in Nasopharyngeal Secretions after Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Detection of IgA and IgG but not IgE antibody to respiratory syncytial virus in nasal washes and sera from infants with wheezing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Undetectable IgE responses after respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Respiratory infections and asthma: current treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Neonatal and early life vaccinology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Protective efficacy against respiratory syncytial virus following murine neonatal immunization with BBG2Na vaccine: influence of adjuvants and maternal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

The future of respiratory syncytial virus vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Second-year surveillance of recipients of a respiratory syncytial virus (RSV) F protein subunit vaccine, PFP-1: evaluation of antibody persistence and possible disease enhancement

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Respiratory syncytial virus: concerns and control

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Immunization against viral respiratory disease: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

In vivo selection of respiratory syncytial viruses resistant to palivizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Variable resistance to palivizumab in cotton rats by respiratory syncytial virus mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Inhibition of respiratory viruses by nasally administered siRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Immunization with a peptide derived from the G glycoprotein of bovine respiratory syncytial virus (BRSV) reduces the incidence of BRSV-associated pneumonia in the natural host

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

The development of a mimotope-based synthetic peptide vaccine against respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Induction of antibody responses in the common mucosal immune system by respiratory syncytical virus immunostimulating complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Oral immunization of mice with transgenic tomato fruit expressing respiratory syncytial virus-F protein induces a systemic immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Protection against respiratory syncytial virus infection by DNA immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

DNA immunization against respiratory syncytial virus (RSV) in infant rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

DNA vaccination against respiratory syncytial virus in young calves

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Gene-gun DNA vaccination aggravates respiratory syncytial virus-induced pneumonitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Pulmonary delivery of respiratory syncytial virus DNA vaccines using macroaggregated albumin particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

CD40 ligand (CD154) improves the durability of respiratory syncytial virus DNA vaccination in BALB/c mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Vaccination of infant macaques with a recombinant modified vaccinia virus Ankara expressing the respiratory syncytial virus F and G genes does not predispose for immunopathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Efficacy of adenovirus-vectored respiratory syncytial virus vaccines in a new ferret model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Attenuated Respiratory Syncytial Virus Vaccines in Asthmatic Children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Recombinant respiratory syncytial viruses with deletions in the NS1, NS2, SH, and M2-2 genes are attenuated in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Granulocyte-macrophage colony-stimulating factor expressed by recombinant respiratory syncytial virus attenuates viral replication and increases the level of pulmonary antigen-presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

The natural history of respiratory syncytial virus infection in cancer and transplant patients: implications for management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.169

21 January 2018

Identifiers

DOI

10.1586/1744666X.2.1.169

1 reference

22 August 2017

1 reference